CEASAR Study Update

Thank you for your continuing participation in the CEASAR study. Our ongoing goal for CEASAR is to help learn more about what treatment works best, for which patients, in whose hands.

- There are 3,693 men with a diagnosis of prostate cancer who are part of the CEASAR Study. Of these, 1,429 chose surgery, 1,004 chose radiation therapy, and 443 chose active surveillance as their initial therapy. We now have information about these men from three surveys done over the past four years.

There have been a number of important findings from the CEASAR Study reported at national meetings and in medical journals.

- The CEASAR team recently published a paper in the Journal of Comparative Effectiveness Research explaining how the CEASAR Study was developed. This information will be helpful for future studies of prostate cancer and other diseases.

- A second paper by the CEASAR team was recently accepted for publication in the journal Cancer that looks at the relationship between age, other medical problems, and urinary, sexual, and bowel function before prostate cancer treatment. The study findings will be used to identify the patients at risk for harms from prostate cancer treatment.

- A third paper describing differences in urinary, sexual, and bowel function before treatment between CEASAR Study participants and another group of patients with prostate cancer from a
The study called PCOS (Prostate Cancer Outcomes Study) has also been prepared for publication by the CEASAR team. This paper found that men in CEASAR reported worse pre-treatment function than men in PCOS almost 20 years ago. These results are important for how we will measure the quality of prostate cancer care in the future.

- Findings from the CEASAR Study have also been presented at important national meetings like the American Urological Association, the American College of Surgeons, and the American Society of Clinical Oncology.

- In September 2013, we received funding from the Patient-Centered Outcomes Research Institute. This agency encourages patient involvement in research. We formed a panel of men who have had prostate cancer to help us in creating the Three Year Follow-up Survey you will find in this packet. Their input has been very important in helping us ask you the right questions that will lead us closer to our goal of helping men with prostate cancer find the best treatment. We have also received funding from the Agency for Healthcare Research & Quality to conduct a five-year follow-up survey with you. We greatly appreciate your continued support of and participation in our efforts.

The Institute of Medicine has ranked comparing the effectiveness of treatments for prostate cancer on survival, recurrence, side effects, quality of life, and costs, as one of the top research priorities in coming years. We hope findings from the CEASAR Study will yield real improvements for men with prostate cancer.

As we move ahead in our efforts to learn from the information gathered from your survey responses, we will continue to keep you up to date on findings. We have created a website called ceasarprostate.org and encourage you to visit it regularly, as we will update it with new results and resources as we move forward.

With your continued participation in CEASAR, we will begin to learn more about the long-term outcomes from prostate cancer treatment, and answer the question “what treatment works best, for which patients, and in whose hands?”

Please visit us on the web for further information, resources and updates
ceasarprostate.org